EcoBioTech

Chemotherapy resistance remains a key contributor to the reduced effectiveness of cancer treatment. The aim of this study was to identify transcriptomic programs associated with the development of docetaxel adaptation in a PC3 cell model of prostate cancer and evaluate their applicability for the subsequent search for modifiers among fungal secondary metabolites. The experimental cells were exposed to docetaxel for prolonged periods, followed by selection of the surviving cell population. Using RNA-seq and GSEA analyses, we identified positive enrichment of the «TNFα signaling via NF-κB», inflammatory response, and «IL6/JAK/STAT3 signaling» pathways, which is consistent with the formation of an NF-κB/IL6/JAK/STAT3-associated survival signature. We also demonstrated the statistical significance of enrichment of the «Cholesterol homeostasis» pathway, suggesting the transcriptional remodeling of cholesterol-associated metabolic programs. The obtained data allow us to consider the identified transcriptomic programs as guidelines for subsequent targeted search and experimental testing of fungal secondary metabolites that are potentially capable of modifying inflammatory signaling and metabolic mechanisms of drug tolerance in tumor cells.

prostate cancer, chemotherapy, docetaxel, cell lines, transcriptome, fungal secondary metabolites

• Bills G.F., Gloer J.B. (2016) Biologically Active Secondary Metabolites from the Fungi. Microbiology Spectrum. 4(6) https://doi.org/10.1128/microbiolspec.FUNK-0009-2016
• Candia J., Ferrucci L. (2024) Assessment of Gene Set Enrichment Analysis using curated RNA-seq-based benchmarks. PloS One. 19(5): e0302696. https://doi.org/10.1371/journal.pone.0302696 EDN: WXMAVI
• Codony-Servat J., Marín-Aguilera M., Visa L., García-Albéniz X., Pineda E., Fernández P.L., Filella X., Gascón P., Mellado B. (2013) Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. The Prostate. 73(5): 512–521. https://doi.org/10.1002/pros.22591
• Cruz-Lozano J.R., Hernández-Flores G., Ortiz-Lazareno P.C., Palafox-Mariscal L.A., Vázquez-Ibarra K.C., González-Martínez K.L., Villaseñor-García M.M., Bravo-Cuellar A. (2024) Improvement of Docetaxel Efficacy through Simultaneous Blockade of Transcription Factors NF-κB and STAT-3 Using Pentoxifylline and Stattic in Prostate Cancer Cells. Current Issues in Molecular Biology. 46(9): 10140–10159. https://doi.org/10.3390/cimb46090605 EDN: ARLBOY
• Dhiman V.K., Kumari M., Singh D. (2026) Chemoresistance: The hidden barrier in cancer treatment. Cancer Pathogenesis and Therapy. 4(2): 98–109. https://doi.org/10.1016/j.cpt.2025.07.001 EDN: ENZRJL
• Don-Doncow N., Escobar Z., Johansson M., Kjellström S., Garcia V., Munoz E., Sterner O., Bjartell A., Hellsten R. (2014) Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. The Journal of Biological Chemistry. 289(23): 15969–15978. https://doi.org/10.1074/jbc.M114.564252
• Ergin S., Kherad N., Alagoz M. (2022) RNA sequencing and its applications in cancer and rare diseases. Molecular Biology Reports. 49(3): 2325–2333. https://doi.org/10.1007/s11033-021-06963-0 EDN: NJOMCK
• Evidente A. (2024) Advances on anticancer fungal metabolites: sources, chemical and biological activities in the last decade (2012-2023). Natural Products and Bioprospecting. 14(1): 31. https://doi.org/10.1007/s13659-024-00452-0 EDN: KBIIXM
• García-Estrada C., Barreiro C., Martín J.F. (2025) Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds. International Journal of Molecular Sciences. 27(1): 101. https://doi.org/10.3390/ijms27010101 EDN: KNCJYK
• Gu Y., Yang R., Zhang Y., Guo M., Takehiro K., Zhan M., Yang L., Wang H. (2025) Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Molecular Biomedicine. 6(1): 2. https://doi.org/10.1186/s43556-024-00239-2 EDN: VIQHEJ
• Guerrero-Ochoa P., Rodríguez-Zapater S., Anel A., Esteban L.M., Camón-Fernández A., Espilez-Ortiz R., Gil-Sanz M.J., Borque-Fernando Á. (2024) Prostate Cancer and the Mevalonate Pathway. International Journal of Molecular Sciences. 25(4): 2152. https://doi.org/10.3390/ijms25042152 EDN: VYHOZP
• Hussain M., Fizazi K., Shore N.D., Heidegger I., Smith M.R., Tombal B., Saad F. (2024) Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. JAMA Oncology. 10(6): 807. https://doi.org/10.1001/jamaoncol.2024.0591 EDN: ZXOZHM
• Ko H., Lee J., Kim H., Kim T., Han Y., Suh Y.-G., Chun J., Kim Y., Ahn K. (2019) Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer. Biomolecules. 9(5): 170. https://doi.org/10.3390/biom9050170 EDN: KKWWNS
• Köpcke B., Weber R.W.S., Anke H. (2002) Galiellalactone and its biogenetic precursors as chemotaxonomic markers of the Sarcosomataceae (Ascomycota). Phytochemistry. 60(7): 709–714. https://doi.org/10.1016/S0031-9422(02)00193-0 EDN: AYCYGD
• Le T.K., Duong Q.H., Baylot V., Fargette C., Baboudjian M., Colleaux L., Taïeb D., Rocchi P. (2023) Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. Cancers. 15(20): 5047. https://doi.org/10.3390/cancers15205047 EDN: YMLWYS
• Menyhart O., Kothalawala W.J., Győrffy B. (2025) A gene set enrichment analysis for cancer hallmarks. Journal of Pharmaceutical Analysis. 15(5): 101065. https://doi.org/10.1016/j.jpha.2024.101065 EDN: QVPJXK
• Pudova E., Kobelyatskaya A., Katunina I., Snezhkina A., Nyushko K., Fedorova M., Pavlov V., Bulavkina E., Dalina A., Tkachev S. et al. (2022) Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939. International Journal of Molecular Sciences. 23(21): 12837. https://doi.org/10.3390/ijms232112837 EDN: CPGQLC
• Sekino Y., Teishima J. (2020) Molecular mechanisms of docetaxel resistance in prostate cancer. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2020.37 EDN: GIONCE
• Siegel R.L., Kratzer T.B., Giaquinto A.N., Sung H., Jemal A. (2025) Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 75(1): 10–45. https://doi.org/10.3322/caac.21871 EDN: MHQXTB
• Sonowal S., Gogoi U., Buragohain K., Nath R. (2024) Endophytic fungi as a potential source of anti-cancer drug. Archives of Microbiology. 206(3): 122. https://doi.org/10.1007/s00203-024-03829-4 EDN: FYOTSP
• Thaper D., Vahid S., Kaur R., Kumar S., Nouruzi S., Bishop J.L., Johansson M., Zoubeidi A. (2018) Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Scientific Reports. 8(1): 17307. https://doi.org/10.1038/s41598-018-35612-z EDN: ODCBXT
• Tripathi S., Gupta E., Galande S. (2024) Statins as anti‐tumor agents: A paradigm for repurposed drugs. Cancer Reports. 7(5): e2078. https://doi.org/10.1002/cnr2.2078 EDN: XJKYLE
• Zafar A., Khatoon S., Khan M.J., Abu J., Naeem A. (2025) Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discover Oncology. 16(1): 607. https://doi.org/10.1007/s12672-025-02198-8 EDN: GYFUQZ
• Zhang S., Shi G., Xu X., Guo X., Li S., Li Z., Wu Q., Yin W.-B. (2024) Global Analysis of Natural Products Biosynthetic Diversity Encoded in Fungal Genomes. Journal of Fungi. 10(9): 653. https://doi.org/10.3390/jof10090653 EDN: XQUNQQ
• Zhang Z., Wang W., Kong P., Feng K., Liu C., Sun T., Sang Y., Duan X., Tao Z., Liu W. (2023) New insights into lipid metabolism and prostate cancer (Review). International Journal of Oncology. 62(6): 74. https://doi.org/10.3892/ijo.2023.5522 EDN: EXURLP
• Zhong W., Wu K., Long Z., Zhou X., Zhong C., Wang S., Lai H., Guo Y., Lv D., Lu J. et al. (2022) Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 10(1): 94. https://doi.org/10.1186/s40168-022-01289-w EDN: LSXQUU